Kevzara (sarilumab)

搜索文档
Regeneron (REGN) Q2 Earnings: How Key Metrics Compare to Wall Street Estimates
ZACKS· 2025-08-01 22:30
Regeneron (REGN) reported $3.68 billion in revenue for the quarter ended June 2025, representing a year-over-year increase of 3.6%. EPS of $12.89 for the same period compares to $11.56 a year ago.The reported revenue compares to the Zacks Consensus Estimate of $3.34 billion, representing a surprise of +9.91%. The company delivered an EPS surprise of +60.52%, with the consensus EPS estimate being $8.03.While investors closely watch year-over-year changes in headline numbers -- revenue and earnings -- and how ...